Scribd Logo
Upload

Welcome to Scribd!

  • Platelet Aggregation, If A Patient With Atherosclerotic Coronary Arteries Who Was Taking Aspirin

    Uploaded by

    mzjackie9
    24 views1 page
    The document discusses how aspirin functions as a platelet aggregation inhibitor by blocking the cyclooxygenase pathway in the metabolism of arachidonic acid released from cell membranes by phospholipase. It notes that while aspirin only stays in the body for a few hours, its effects on platelets are permanent for the lifespan of the platelet. This means that for a patient taking aspirin who experiences a plaque rupture in their atherosclerotic coronary arteries, the possibility of a thrombus forming is reduced, which could mean the difference between life and death from a myocardial infarction.

    Original Description:

    platelet

    Original Title

    Platelet

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The document discusses how aspirin functions as a platelet aggregation inhibitor by blocking the cyclooxygenase pathway in the metabolism of arachidonic acid released from cell membranes by phospholipase. It notes that while aspirin only stays in the body for a few hours, its effects on platelets are permanent for the lifespan of the platelet. This means that for a patient taking aspirin who experiences a plaque rupture in their atherosclerotic coronary arteries, the possibility of a thrombus forming is reduced, which could mean the difference between life and death from a myocardial infarction.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as docx, pdf, or txt
    24 views1 page

    Platelet Aggregation, If A Patient With Atherosclerotic Coronary Arteries Who Was Taking Aspirin

    Uploaded by

    mzjackie9
    The document discusses how aspirin functions as a platelet aggregation inhibitor by blocking the cyclooxygenase pathway in the metabolism of arachidonic acid released from cell membranes by phospholipase. It notes that while aspirin only stays in the body for a few hours, its effects on platelets are permanent for the lifespan of the platelet. This means that for a patient taking aspirin who experiences a plaque rupture in their atherosclerotic coronary arteries, the possibility of a thrombus forming is reduced, which could mean the difference between life and death from a myocardial infarction.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as docx, pdf, or txt
    of 1

    The pathway diagrammed below should look vaguely familiar to you from your previous discussion on inflammation.

    Recall that when properly activated during the inflammatory process, phospholipase will cause the release of arachidonic acid from cell membranes, which will then be further metabolized via either the cyclooxygenase or lipoxygenase pathway. As a reminder, aspirin (acetylsalicylic acid) functions as a platelet aggregation inhibitor by blocking the cyclooxygenase pathway. It only stays in the body for a few hours but the effects of aspirin on platelets are permanent and last for the life of the platelet exposed. Since aspirin mitigates platelet aggregation, if a patient with atherosclerotic coronary arteries who was taking aspirin were to experience a plaque rupture, the possibility of a thrombus forming on the ruptured area would be reduced; in some cases that could mean the difference between life and death due to a myocardial infarction. Phospholipase s Aspiri n Arachidonic Acid

    5-Lipoxygenase 5-HPETE

    Cyclooxygenase Prostaglandin G2

    Leukotriene A4 Leukotriene C4 Leukotriene D4 Leukotriene E4 PGD2

    Prostaglandin H2 Prostacyclin Thromboxane A2

    PGE2

    PGF2

    You might also like